21 September 2024 - Hetronifly (serplulimab) is expected to become the first anti-PD-1 monoclonal antibody available in Europe for first-line treatment of extensive-stage small cell lung cancer.

Intas Pharmaceuticals has announced that the CHMP of the EMA has issued a positive opinion recommending approval of Hentronifly (serplulimab), in European markets.